万赛维怎么服用？

It is a treatment drug used by many patients with viral retinitis in recent years. For many people, there are many things to pay attention to in life when using drugs to treat diseases, including drug safety, dietary issues, work and rest, etc. So, how should patients take Vancevir?

When Vancevi is used to prevent CMV infection in organ transplants in adult patients, for kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Special Dosage Guidelines in Patients with Renal Impairment: Serum creatinine or creatinine clearance levels should be monitored closely. Dosage adjustments should be made based on creatinine clearance as shown below. For CrCl ≥ (greater than or equal to) 60 mL/min, the induction dose is 900 mg, twice a day; the maintenance dose is 900 mg, once a day. If the CrCl is 40-59 mL/min, the induction dose is 450 mg, twice a day; the maintenance dose is 450 mg, once a day. If the CrCl is 25-39 mL/min, the induction dose is 900 mg, once a day; the maintenance dose is 900 mg, once every other day. If the CrCl is 10-24 mL/min, the induction dose is 900 mg, once every other day; the maintenance dose is 900 mg, twice a week. The creatinine clearance rate can be estimated based on serum creatinine according to the following formula: Male = [140-age (years) x weight (kg) ÷ (72) x [0.011 x serum creatinine (umol/L)]. Female = 0.85 × male value. Patients undergoing hemodialysis: For patients undergoing hemodialysis (CrCl<10 mL/min), no recommended dose can be given, so Vancevi cannot be used in such patients. Patients with severe leukopenia, neutropenia, anemia, thrombocytopenia and pancytopenia: Cases of severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow suppression and aplastic anemia have occurred in patients treated with Vancevir (or cyclovir). Do not initiate treatment with Vancevir if the absolute neutrophil count is less than 500/uL, the platelet count is less than 25,000/uL, or the hemoglobin is less than 8 g/dl.

Contraindications: Patients with known allergic reactions to valganciclovir, ganciclovir or any other ingredients in the drug should not use Valganciclovir Hydrochloride Tablets. Due to the similar chemical structures of valganciclovir hydrochloride tablets to acyclovir and valacyclovir, cross-allergic reactions may exist between these drugs.